Document registry — page 20
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with GHK-Cu compared with its…
Low02 Dec 2025 -
Event-driven cardiovascular outcome trial, phase 3 study of Tirzepatide in cardiovascular and type 2 diabetes randomising 13,299 participants over median 4.5 years…
Moderate28 Nov 2025 -
Consultation on the draft standard for bacterial endotoxin testing of peptide presentations, which specifies the performance a determination must achieve and the…
23 Nov 2025 -
Consultation on the draft monograph for Ipamorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
23 Nov 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, is the effect of Teduglutide maintained across the full duration of the…
Moderate22 Nov 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its…
Moderate20 Nov 2025 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the effect of Tesamorelin compared with the comparator used in its…
Moderate19 Nov 2025 -
Dual glucagon and GLP-1 receptor agonist (acylated). Glucagon receptor agonism increases hepatic fatty-acid oxidation, resting energy expenditure and hepatic lipid clearance; GLP-1 receptor agonism…
Moderate19 Nov 2025 -
Single-arm open-label, phase 3 study of Mazdutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low18 Nov 2025 -
In the population defined for obesity and overweight in adults, is the effect of Retatrutide maintained across the full duration of the contributing trials?
Moderate16 Nov 2025 -
In the population defined for obesity and overweight in adults, is the effect of Liraglutide maintained across the full duration of the contributing trials?
High15 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Tirzepatide compared with the comparator…
Moderate13 Nov 2025 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the effect of SS-31 (elamipretide) compared with the comparator used in…
Moderate11 Nov 2025 -
Peptides, SARMs, injectable oils and raw materials.
11 Nov 2025 -
Consultation on the draft synthesis of weight trajectory after an incretin receptor agonist is stopped. The contributing evidence is drawn principally from the…
05 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide, oral compared with the…
Moderate01 Nov 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity randomising 664 participants over 48 weeks. Primary result: Mean change −13.2 % at…
Low01 Nov 2025 -
Adiposity above the 95th percentile for age and sex, or above the 120th percentile of the 95th percentile for severe obesity, in individuals under 18 years.
31 Oct 2025 -
Consultation on the draft monograph for Thymalin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
25 Oct 2025 -
In adults at elevated cardiovascular risk, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on major adverse cardiovascular events?
High24 Oct 2025 -
Consultation on the draft monograph for CagriSema (cagrilintide with semaglutide), which the assessment committee released for public comment before ratification. The…
22 Oct 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the…
High22 Oct 2025 -
In the population defined for obesity and overweight in adults, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its…
Moderate17 Oct 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent…
Very low15 Oct 2025 -
Consultation on the draft monograph for Semax, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
14 Oct 2025 -
Acetylated heptapeptide fragment of thymosin beta-4. Thymosin beta-4 is an abundant intracellular actin-sequestering protein with reported extracellular activity in angiogenesis, cell migration and…
Very low13 Oct 2025 -
What is the incidence of gastrointestinal adverse events and of discontinuation for adverse events with incretin receptor agonists compared with placebo?
High12 Oct 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Kisspeptin-10 compared with the comparator…
Moderate11 Oct 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High09 Oct 2025 -
Observational, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Oct 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor…
High04 Oct 2025 -
Consultation on the draft monograph for NAD+ (nicotinamide adenine dinucleotide), which the assessment committee released for public comment before ratification. The…
29 Sep 2025 -
Consultation on the draft of CEI-MS-12, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish…
29 Sep 2025 -
Consultation on the draft monograph for Tesamorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
28 Sep 2025 -
In the population defined for obstructive sleep apnoea with obesity, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on…
High27 Sep 2025 -
Single-arm open-label, phase 3 study of Ecnoglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low26 Sep 2025 -
Consultation on the draft analytical evidence review of published surveys of unregulated peptide supply. The review assesses what such surveys establish, and records…
24 Sep 2025 -
GLP-1 receptor agonist, Fc-fusion protein. Receptor pharmacology is that of the selective GLP-1 class, delivered from a large fusion protein. Because the molecule is above the renal filtration…
High23 Sep 2025 -
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide). Ghrelin receptor agonism with pronounced growth-hormone release, marked appetite stimulation, and concomitant elevation of cortisol and…
Very low21 Sep 2025 -
In the population defined for cutaneous wound healing and tissue repair, what is the effect of GHK-Cu compared with the comparator used in its contributing trials on the…
Low19 Sep 2025
page 20 of 41